A new study looks at emotionally painful, shame-related processes with psychedelic use. The post New Study Looks at Shame, Guilt and the Psychedelic Experience...
The soon-to-issue patent contains composition of matter and methods of use claims for a family of novel prodrug derivatives of psilocybin. The post Enveric...
A bipartisan group of congressional lawmakers from both the House and the Senate have added funding for studies of psychedelic therapies into a major defense...
Potentially groundbreaking results as Cybin's Phase 2 Study of CYB003 in Major Depressive Disorder showed 79% of patients in remission after two 12mg doses. The...
Seventy health professionals, scientists, scholars, and aficionados of altered states of consciousness gathered in Corralejo, Fuerteventura, for the 2nd...
For those interested in ketamine treatment, there is a vast array of potential therapies designed to meet you where you’re at.
Exploring the implications of the recent Burlington mushroom bust, and how it impacts the psychedelic movement.
Beckley Retreats, a psilocybin retreats and holistic wellbeing company, announced today the launch of the Beckley Retreats Scholarship Program beginning...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) is pleased to announce the successful resolution of a dispute...